Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Recent advances in treatments for congenital adrenal hyperplasia

Nature Reviews Endocrinology volume 21, pages 197–198 (2025)Cite this article

Subjects

The first CRFR1 antagonist (crinecerfont) to be used for the treatment of congenital adrenal hyperplasia recently received FDA approval. This Clinical Outlook discusses the latest phase III studies in children and adults, as well as how crinecerfont — in combination with glucocorticoid replacement — might change clinical practice and affect long-term co-morbidities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Claahsen-van der Grinten, H. L. et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr. Rev. 43, 91–159 (2022).

    Article  PubMed  Google Scholar 

  2. Auer, M. K., Nordenström, A., Lajic, S. & Reisch, N. Congenital adrenal hyperplasia. Lancet 401, 227–244 (2023).

    Article  PubMed  CAS  Google Scholar 

  3. Whitaker, M. J., Huatan, H. & Ross, R. J. Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm. Drug Deliv. Transl. Res. 13, 1–8 (2023).

    Article  PubMed  CAS  Google Scholar 

  4. Auchus, R. J. et al. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N. Engl. J. Med. 391, 504–514 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Sarafoglou, K. et al. Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N. Engl. J. Med. 391, 493–503 (2024).

    Article  PubMed  CAS  Google Scholar 

  6. Domin, H. & Śmiałowska, M. The diverse role of corticotropin-releasing factor (CRF) and its CRF1 and CRF2 receptors under pathophysiological conditions: Insights into stress/anxiety, depression, and brain injury processes. Neurosci. Biobehav. Rev. 163, 105748 (2024).

    Article  PubMed  CAS  Google Scholar 

  7. Lawrence, S. & Scofield, R. H. Post traumatic stress disorder associated hypothalamic-pituitary-adrenal axis dysregulation and physical illness. Brain Behav. Immun. Health 41, 100849 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Pandey, G. N., Rizavi, H. S., Bhaumik, R. & Ren, X. Increased protein and mRNA expression of corticotropin-releasing factor (CRF), decreased CRF receptors and CRF binding protein in specific postmortem brain areas of teenage suicide subjects. Psychoneuroendocrinology 106, 233–243 (2019).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Mantsch, J. R. Corticotropin releasing factor and drug seeking in substance use disorders: preclinical evidence and translational limitations. Addict. Neurosci. 4, 100038 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ibarguen-Vargas, Y., Leman, S., Palme, R., Belzung, C. & Surget, A. CRF-R1 antagonist treatment exacerbates circadian corticosterone secretion under chronic stress, but preserves HPA feedback sensitivity. Pharmaceutics 13, 2114 (2021).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

    Henrik Falhammar

  2. Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden

    Henrik Falhammar

  3. Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

    Svetlana Lajic & Anna Nordenström

  4. Pediatric Endocrinology Unit, Karolinska University Hospital, Stockholm, Sweden

    Svetlana Lajic & Anna Nordenström

  5. Department of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Svetlana Lajic

Authors
  1. Henrik Falhammar
    View author publications

    Search author on:PubMed Google Scholar

  2. Svetlana Lajic
    View author publications

    Search author on:PubMed Google Scholar

  3. Anna Nordenström
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Anna Nordenström.

Ethics declarations

Competing interests

H.F. has been an investigator for studies and received consultation fees from Neurocrine Inc., Spruce Bioscience Inc. and H. Lundbeck A/S. S.L. has received consultation fees from Merck and Immedica. A.N. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falhammar, H., Lajic, S. & Nordenström, A. Recent advances in treatments for congenital adrenal hyperplasia. Nat Rev Endocrinol 21, 197–198 (2025). https://doi.org/10.1038/s41574-025-01089-w

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41574-025-01089-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing